Ipamorelin
GHRP (selective)
Ipamorelin is a growth-hormone secretagogue — a peptide that prompts your own pituitary to release growth hormone — and it earned a reputation as the 'cleanest' of its class. Described in 1998 as the first truly <b>selective</b> GH secretagogue, it stimulates GH without the cortisol, prolactin and appetite spikes of older peptides. This guide covers how ipamorelin works, what the research shows, dosing references, safety and status.
Ipamorelin quick facts
| Reported research dosing | 100mcg-500mcg |
| Route | Subq |
| Cycle length | 3-6 Months |
| Frequency | 1-3x Daily AM/Workout/PM · 5 On 2 Off or Daily |
| Half-life | ~2 hrs |
| Forms | Injectable |
| Evidence level | Human PK on components |
The cleanest GHRP. Synergizes hard with a GHRH like CJC no-DAC.
How ipamorelin works
Ipamorelin is a ghrelin-receptor (GHSR-1a) agonist: it binds the growth-hormone-secretagogue receptor in the pituitary and triggers a pulse of natural growth-hormone release. Crucially, it works with your physiology rather than overriding it — it preserves the natural pulsatile rhythm of GH and keeps normal feedback regulation intact, unlike exogenous HGH, which replaces your own GH and suppresses the axis.
Why ipamorelin is called 'selective'
The reason ipamorelin is so popular is selectivity. Earlier GHRPs like GHRP-2 and GHRP-6 raised GH but also bumped cortisol, prolactin and appetite. Ipamorelin stimulates GH at levels comparable to GHRP-6 while producing no statistically significant rise in cortisol or ACTH at research doses, and — unlike other ghrelin agonists — it doesn't significantly spike hunger. That cleaner profile is why it's a go-to in GH-support research and is often paired with a GHRH.
What the research shows
Ipamorelin was originally developed by Novo Nordisk and studied in Phase I/II trials. The published research spans body-composition changes in animal models, bone-density research, and gut-motility studies (GH secretagogues can promote GI motility). As with most peptides in this space, the enthusiasm is built on a mix of mechanism, early clinical work and anecdote rather than large long-term human outcome trials.
Ipamorelin dosing (research reference)
The literature commonly references ipamorelin in the low-hundreds-of-micrograms range per dose, often once to a few times daily and frequently timed around sleep or fasting to align with natural GH pulses, reconstituted with bacteriostatic water. The calculator above converts a research amount into syringe units. It's frequently referenced stacked with a GHRH such as CJC-1295 for a stronger, more synergistic pulse. This summarizes existing references for education only, not dosing advice.
Safety & side effects
Ipamorelin's selectivity is exactly why it's considered one of the better-tolerated secretagogues — minimal cortisol/prolactin effect and little appetite change at research doses. That said, GH-axis stimulation still warrants care (water retention, effects on insulin sensitivity and blood sugar are worth understanding), long-term human safety data is limited, and research-market purity varies. This is educational information, not medical advice.
Related compounds & stacking
Ipamorelin (a GH-releasing peptide) is classically paired with a GHRH like CJC-1295 — the two hit the GH axis through different receptors, producing a bigger combined pulse than either alone. It sits in the same GH-support family as MK-677, Sermorelin and Tesamorelin.
Legal & regulatory status
Ipamorelin is not FDA-approved and is sold as a research compound (research use only). GH secretagogues are also prohibited in competitive sport under WADA. Its compounding status is subject to ongoing FDA review. Follow the laws and any sport rules that apply to you.
✅ Clinically validated
- Human pharmacokinetic and tolerability data exist from its development as a treatment for post-operative ileus — it reached phase 2 and did not meet that endpoint, so the indication was dropped.
- Note what was being asked. The endpoint was return of gut motility after abdominal surgery, not growth hormone release — and ipamorelin's GH activity was never in question in that programme; it was demonstrated in the same trials as a pharmacodynamic marker. A failure to speed up post-surgical bowel function says nothing about whether it raises GH, which it measurably does. The dosing and safety characterisation from that programme is why its human profile is better described than most peptides here.
📊 Correlative data
- The most widely used GH secretagogue in practice, usually paired with a GHRH analogue. What clinicians and users consistently report is the thing the receptor selectivity predicts: a GH pulse without the hunger, cortisol rise or prolactin rise that the older secretagogues cause.
🧪 Theoretical / extrapolated
- A selective ghrelin-receptor (GHS-R1a) agonist. Selectivity is the entire point — GHRP-6 and GHRP-2 hit the same receptor but also drive ACTH, cortisol and prolactin, and ipamorelin largely does not.
- Because it works through a different receptor from the GHRH analogues, the two are predicted to be additive rather than redundant, which is exactly why the CJC/ipamorelin pairing became standard.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Ipamorelin — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Fasted — and pre-bed is the best of the windows
Food is the problem here, and specifically carbohydrate and fat. Both trigger somatostatin release, and somatostatin is the brake on growth hormone — eating before the injection pharmacologically cancels it. Two clear hours either side.
Pre-bed is the strongest window because the largest natural GH pulse happens in the first hours of deep sleep, so you are stacking with it rather than asking the pituitary for something it is not primed for. Fasted pre-training is the second-best, for the same reason in a different rhythm.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Ipamorelin reconstitution calculator
Research reconstitution calculator
Where to get Ipamorelin
Buy Ipamorelin at AminoWell USA →Ipamorelin — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Ipamorelin moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- IGF-1 (Insulin-like Growth Factor 1) — ↑ expected to rise
This is the point. IGF-1 rising is the compound doing its job — it is the stable downstream readout of a GH pulse.
What to do: Test it before you start and again at 6–8 weeks. It is the only number that tells you whether the product was real and the dose was enough. - Growth Hormone, Serum — ✕ unreliable here
A random GH level is close to meaningless here. GH is secreted in pulses during deep sleep and sits undetectable between them, so a daytime draw catches a trough almost every time — including when the compound is working perfectly.
What to do: Do not use GH to judge a secretagogue. Read IGF-1 instead. - Fasting Insulin — ↑ expected to rise
GH is a counter-regulatory hormone: it opposes insulin. Fasting insulin and glucose drifting up is the predicted trade-off, not a surprise.
What to do: Check fasting insulin and HbA1c at baseline and again at 8–12 weeks. This is the marker that decides whether you keep running it. - HbA1c (Hemoglobin A1c) — ↑ expected to rise
Same mechanism, longer window — a slow drift rather than a jump.
What to do: Pair it with fasting insulin; either alone can mislead. - Free T4 (Thyroxine) — ↓ expected to fall
GH accelerates the peripheral conversion of T4 to T3, so free T4 can fall while free T3 holds or rises. Read alone it looks like new hypothyroidism, and it usually isn't.
What to do: Run a full thyroid panel rather than TSH alone before concluding anything.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Ipamorelin — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Everything above follows from one fact: these raise GH and therefore IGF-1. Nothing here needs a trial of the specific molecule.
Bloodwork to run alongside Ipamorelin
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| IGF-1 (Insulin-like Growth Factor 1) | What you dose against — feel is not a measurement |
| Fasting Insulin | The trade that comes with every GH secretagogue |
| HbA1c (Hemoglobin A1c) | Three-month confirmation |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose and organ baseline |
The Running GH Peptides or MK-677 panel covers these in one order — 9 markers, $132.30 with the discount applied.
Check results you already have → · All 102 markers A–Z
Ipamorelin — frequently asked questions
What is ipamorelin?
Ipamorelin is a selective growth-hormone secretagogue — a peptide that binds the ghrelin receptor to prompt your own pituitary to release a pulse of growth hormone, without the cortisol and appetite spikes of older GHRPs.
How does ipamorelin work?
It's a ghrelin-receptor (GHSR-1a) agonist that triggers a natural, pulsatile release of growth hormone while preserving normal feedback regulation, rather than replacing your own GH the way injected HGH does.
Why is ipamorelin considered 'clean'?
It stimulates GH comparably to older GHRPs but without a significant rise in cortisol, prolactin or ACTH, and without much appetite increase — a more selective profile than GHRP-2 or GHRP-6.
How is ipamorelin dosed?
The literature references low-hundreds-of-micrograms per dose, often around sleep or fasting to match natural GH pulses, reconstituted with bacteriostatic water (see calculator). It's frequently referenced stacked with a GHRH. This is educational, not dosing advice.
What does ipamorelin stack well with?
It's classically paired with a GHRH like CJC-1295 — the two act on different receptors to produce a larger combined GH pulse than either alone.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved and is sold as a research compound. GH secretagogues are also banned in competitive sport under WADA.
References & further reading
- Ipamorelin — the first selective growth-hormone secretagogue (1998 paper)
- The growth-hormone secretagogue receptor — signaling & regulation (PMC)
- Ipamorelin research profile (Regen Peptides)
Want Coach Cam's exact Ipamorelin protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Ipamorelin is used for
Ipamorelin appears under 3 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.